Anti-VEGF Therapy and Ocular Diseases

Ocular angiogenesis causes severe global vision loss and eye disease morbidity. However, anti-vascular endothelial growth factor (anti-VEGF) has become the most common treatment modality for many retinal disorders, including neovascular age-related macular degeneration (n-AMD), proliferative diabetic retinopathy (PDR), retinal vein occlusion (RVO), etc. VEGF is a highly specific endogenous pro-vascular endothelial growth factor. Under normal physiological conditions, VEGF secretion helps rebuild epithelial cells to build functional blood vessels. VEGF upregulation contributes to increased vascular permeability, extracellular matrix degeneration, vascular endothelial cell migration and proliferation, and angiogenesis. Clinically, anti-VEGF therapy has revolutionized the treatment of angiogenesis-related retinal diseases by reducing vascular permeability and reducing the growth and leakage of newly formed blood vessels involved in choroidal and retinal neovascularization.

Fig. 1. Representative molecular modalities of different anti-VEGF agents to treatment of ocular angiogenesis. (Formica ML, et al., 2021)

Service Overview

Biologics targeting vascular endothelial growth factor (VEGF) are the most common primary treatment for many retinal diseases. Ace Therapeutics has a professional biologics product development team to support your project from start to finish.

Multiple processes must be followed in the development of a biological product, from initial drug research to preclinical testing. Ace Therapeutics can develop a customized product development process for your project according to the molecular model (aptamer, mAb or RFP) of the anti-VEGF drug you are interested in. For the anti-VEGF drug you are interested in, our talented scientists provide a complete biologics product development service.

Here, we provide one-stop services from antigen preparation to lead antibody production and lead antibody optimization. Beyond that, our scientists are more than happy to collaborate with your in-house team to accelerate your project development.

Due to the short duration and low effective concentration of anti-VEGF drugs in the eye, intravitreal injection, scleral implant and subconjunctival injection are mostly used for the treatment of neovascular eye diseases. What attracts our customers is that our talented scientists have developed several anti-VEGF drug sustained-release strategies to meet the above requirements that is the anti-VEGF drugs are encapsulated with polymer materials (hydrogel, chitosan, liposome, etc.) to achieve sustained release purposes.

Explore Our Technology Platforms

Ace Therapeutics has established several core technology platforms, including hybridoma, phage display, yeast display and B cell screening methods for biologics discovery to meet any of your needs.

• Hybridoma Sequencing
• Phage Display
• Yeast Display
• Single Cell B Screening

Ace Therapeutics offers extensive professional support for anti-VEGF ophthalmic product development. Thanks to our systematic drug discovery platform, our talented scientists can provide you with high-quality services, significantly reduce project development costs and facilitate clinical trials. If you are interested in our services or need more detailed information, please feel free to contact us. Our experienced scientists are ready to help you!

Reference

1. Formica ML, Awde Alfonso HG, Palma SD. Biological drug therapy for ocular angiogenesis: Anti-VEGF agents and novel strategies based on nanotechnology. Pharmacol Res Perspect. 2021;9(2):e00723.

• Development of Anti-Inflammatory Therapy for Ocular Diseases

• * Name:
• Phone:
• * Email:
• * Services or Products of Interest:
• Project Description:
• * All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

  * Tick to confirm the Research Use Only (RUO) statement.

• Submit